Tech Company Financing Transactions
NAVAN Technologies Funding Round
On 4/26/2019, NAVAN Technologies secured Seed funding from Amgen Ventures, Hemi Ventures and High-Tech Gründerfonds.
Transaction Overview
Company Name
Announced On
4/26/2019
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to: further platform development, scale-up production capabilities, and facilitate strategic collaborations and partnerships to accelerate the development of therapeutics programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells. The Nanostraw technology, exclusively licensed from Stanford University, provides direct intracellular access into hard-to-transfect primary human cells for efficient delivery of any cargo.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ryan Swoboda
Chief Scientific Officer
Sergio Leal-Ortiz
Chief Technical Officer
Martin Hjort
Co-Founder
Craig Garner
Co-Founder
Nicholas Melosh
Co-Founder
Chris Rehse
Browse more venture capital transactions:
Prev: 4/26/2019: Meru Health venture capital transaction
Next: 4/26/2019: Simergent venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs